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Capsule endoscopy (CE) has been increasingly used for diagnosing disease of the small bowel. It is an attractive technique for
assessing celiac disease (CD) because it is noninvasive and provides a close and magniﬁed view of the mucosa of the entire small
bowel. The aim of this paper is to update the current data on the use of CE for diagnosing villous atrophy and complications of
CD.
Celiac disease (CD) is a chronic autoimmune enteropathy
occurring in genetically predisposed individuals following
ingestion of wheat gluten and related protein fractions of
other grains [1]. CD is the most frequently seen enteropathy
in western countries, and its prevalence is 0.7–2% [2].
Patients present with diarrhea, weight loss, steatorrhea, or
malnutrition syndromes such as anemia and diminished
bone mass due to deﬁciencies of important nutrients (iron,
folate, calcium, and fat-soluble vitamins) [3]. However, the
increased interest for this pathology over the last 2 decades
allowed diagnosing CD also in those with the silent or
“atypical” form. These patients may present vague and
subclinical manifestations such as dyspeptic symptoms or
esophageal reﬂux, irritable bowel syndrome, polyneuropa-
thy, or iron deﬁciency anemia [4]. The analogy of an iceberg
was suggested for CD, meaning that only a small portion of
patients with classic symptoms are diagnosed, whereas the
majority of asymptomatic individuals or subjects with mild,
nonspeciﬁc symptoms remain undiagnosed and untreated
[5]. On the other hand, growing body of evidence shows
that early diagnosis and treatment can reduce the risk of
malignant complications, such as lymphoma [6].
The ﬁrst step in pursuing a diagnosis for CD is a sero-
logical test. Serologic tests, particularly the immunoglobulin
A (IgA) antiendomysial (AEA) and the IgA tTGA, have
become a relatively sensitive and speciﬁc way to initially
detect CD. Many studies demonstrate a speciﬁcity of IgA
tTGA greater than 95% and a sensitivity in the range of
90%–96%. AEA has a slightly lower and variable sensitivity
but an excellent speciﬁcity (99,6%). Although the sensitivity
and speciﬁcity of these tests are high, false-negative results
can occur in mild enteropathy and in patients with IgA
deﬁciency [7]. By contrast, antigliadin antibody (AGA) tests
arenolongerusedroutinelybecauseoftheirlowersensitivity
and speciﬁcity. However, a second generation AGA test
(Deamidated Gliadin Peptide (DGP)) yielded far higher
diagnostic accuracy (sensitivity 94 percent, speciﬁcity 99
percent) [8].
Genetic testing may be helpful for the diagnosis. It is
well known that CD is strongly associated with speciﬁc HLA
class II genes known as HLA-DQ2 and HLA DQ8 located on
chromosome 6p21. Most CD patients (around 90%) express
HLA-DQ2 and the remaining patients are usually HLA DQ8
positive. However, it is well known that only around 3–
5% of DQ2- or DQ8-expressing patients actually develop
CD. Thus, HLA DQ2 or HLA DQ8 is necessary for disease
development but not suﬃcient. Non-HLA genes contribute
more than HLA to the CD genetic background. However,
this predisposition depends on a multitude of genes, each of
them adding only a modest contribution to disease develop-
ment. Several genome-wide studies have implicated strong
candidate regions for alternative susceptibility loci including
11p11, 5q31, and 19q13.4 [9].
The gold standard for the diagnosis of CD is histopathol-
ogy of the small bowel. A small intestinal biopsy, which
typically shows villous atrophy, increased intraepithelial2 Gastroenterology Research and Practice
lymphocytes and hyperplastic crypts in patients with CD
[10]. Endoscopic markers suggestive of CD are reduction in
numberorlossofKerckring’sfolds,mosaicpattern,scalloped
folds, and visibility of the underlying blood vessels. These
signs cannot reliably predict CD. The reported speciﬁcity
for endoscopic markers ranges from 87% to 100% but this
markers are considered to lack sensitivity with a reported
range from 50% to 94% [11, 12]. Recognition of endoscopic
signs of CD could help to select patients for biopsy and avoid
delays in the diagnosis of the disease, preventing long-term
complication.
Duodenal biopsy may be limited by patient’s aversion
to undergo upper gastrointestinal (GI) endoscopy, especially
in asymptomatic patients; other limitations include the
diﬃculty of obtaining adequate and properly oriented tissue
samples, the occurrence of patchy mucosal lesions that can
be missed by the biopsy, and, in some cases, the most severe
mucosal changes occur in the jejunum, which is not accessi-
ble to conventional upper GI endoscopy [13].
Capsule endoscopy (CE) is a diagnostic imaging method
used in several intestinal diseases [14–22]. It produces high-
quality images of the small bowel mucosa, with an eightfold
magniﬁcation and has been shown to be superior to other
diagnostic tools for the diagnosis of a variety of diseases,
including refractory CD [17, 23–30]. The main advantages
of CE are that it is noninvasive, it images the entire length
of the small bowel, and it is able to detect minute mucosal
details, including changes in intestinal villi.
There are frequently published studies on the role of CE
in the diagnosis of CD. In general, most endoscopic markers
of CD as described in literature are seen with greater clarity
by CE. At CE, the mucosa in CD may appear scalloped. The
mosaicappearanceofthemucosaisalsoapparent.InCD,the
villi may appear shortened and thickened, layered or stacked
folds. In addition to general mucosal pattern, CE can easily
recognize ﬁnger-like villi [22, 31]. We observed scalloping of
the folds, mosaic pattern, nodularity, and layering of folds in
CE of our patients with CD (Figure 1).
Petroniene et al. showed that the extent of bowel involve-
ment appears to correlate with the severity of symptoms
[10]. Rondonotti et al. exploited the capability of the CE
to evaluate the longitudinal extent of mucosal involvement
beyond the duodenum and its correlation with clinical and
biochemical parameters [32]. In fact, Murray and colleagues
demonstrated that the length of bowel involved did not
correlate with the mode of symptomatic presentation in
patients [33].
A few studies have been published comparing duodenal
biopsy and CE regarding the villous atrophy occurring in
intestinal mucosa in CD (Table 1)[ 32, 34–38]. Petroniene et
al. compared 10 CD patients with histologically proven vil-
lous atrophy with 10 control patients with normal histology.
Sensitivity, speciﬁcity, positive predictive value (PPV), and
negative predictive value (NPV) of CE in diagnosing villous
atrophy were 70%, 100%, 100%, and 77%, respectively [34].
Hopper et al. showed that 17 out of 20 patients with CD
had villous atrophy also were detected by CE. In this paper,
the sensitivity, speciﬁcity, PPV, and NPV for CE in recog-
nising villous atrophy were 85%, 100%, 100%, and 88.9%,
respectively.UpperGIendoscopydetectedendoscopicmark-
ers consistent with CD in 16 out of 20 CDs with a
sensitivity, speciﬁcity, PPV, and NPV of 80%, 100%, 100%,
and 85.7%, respectively. CE was more sensitive than con-
ventional endoscopy in identifying endoscopic markers, but
thediﬀerenceobserveddidnotachievestatisticalsigniﬁcance
[35].Rondonottietal.comparedCEwithduodenalbiopsyin
patients with signs and/or symptoms suggestive of CD and
positive serology. CE was reported to have a sensitivity of
87.5% andspeciﬁcityof90.9%, withPPV, andNPVof 96.5%
and 71.4%, respectively, and positive and negative likelihood
ratios of 9.6 and 0.14, respectively [32].
Biagi et al. did not conﬁrm this data. In this study, the
authors evaluated whether there was a correlation between
the degree of villous atrophy at the histology and CE
results. CE ﬁndings regarding the degree of small bowel
mucosal atrophy showed only a moderate agreement with
the histologic pattern, with a high sensitivity (90.5%–95.2%)
but a low speciﬁcity (63.6%). PPV was 100% and NPV
ranged 77.8% and 87.5% [36]. Maiden et al. compared
CE with histological specimens of proximal small bowel in
patients with CD who had failed to respond to a gluten-free
diet. CE was reported to be normal in ten (53%) cases,
have mild-moderate changes in three (16%) cases, and have
moderate-severe changes in six (31%) cases. Endoscopy
demonstratedconcordancewithhistologicalchangesin14of
the 18 patients with histology available (78% concordance).
Compared with distal duodenal biopsy, CE showed sensitiv-
ity 67%, speciﬁcity 100%, PPV 100%, and NPV 60% [37].
Lidums et al. compared suspected CD patients (positive
celiac serology and normal duodenal histology) and known
CD patients (positive celiac serology and villous atrophy),
withCE,whetherthesepatientshaveanyendoscopicmarkers
ofCD.Inthispaper,thesensitivity,speciﬁcity,PPV,andNPV
forCEinrecognisingvillousatrophywere93%,100%,100%,
and 89%, respectively [38].
In our study, 8 untreated patients who had AEA positive
and duodenal biopsy results consistent with CD were
evaluated. We have shown that CE provided no diagnostic
contribution to CD when compared with duodenal biopsy
[22].
CE also may be helpful in patients with CD with symp-
tomatic relapse or refractory CD and in elderly patients with
atypical symptoms or chronic iron deﬁciency anemia [39].
Culliford et al. showed that, among 47 patients with com-
plicated CD, almost 50% had lesions detected by CE. One
adenocarcinoma was identiﬁed; however, ulceration was
common [40].
The complications of long-standing CD include lym-
phoma, ulcerative jejunitis, and adenocarcinoma. Conse-
quently, those patients develop a recurrence of diarrhea,
fever, abdominal pain, or evidence of GI bleeding. These
complications are often not identiﬁable by conventional
imaging modalities as they are located beyond the site reach-
able by traditional endoscopy. CE should be performed early
when these symptoms occur [31] .C Eh a sb e e nr e p o r t e dt o
be able to demonstrate intussusceptions, ulcerative jejunoil-
eitis, lymphoma, and adenocarcinoma in patients with CDGastroenterology Research and Practice 3
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Figure 1: Capsule endoscopy images of celiac disease. (a) scalloping; (b) mosaic pattern; (c) micronodularity; (d) layering of folds.
Table 1: Summary of the trials sensitivity, speciﬁcity, PPV, NPV of capsule endoscopy in celiac disease.
Study n Country Sensitivity Speciﬁcity PPV NPV
Petroniene et al. [34] 10 Canada 70% 100% 100% 77%
Hopper et al. [35] 21 UK 85% 100% 100% 88.9%
Rondonotti et al. [32] 32 Italy 87.5% 90.9% 96.5% 71.4%
Biagi et al. [36] 26 Italy 90.5–95.2% 63.6% 100% 77.8–87.5%
Maiden et al. 37] 19 UK 67% 100% 100% 60%
Lidums et al. [38] 22 Australia 93% 100% 100% 89%
PPV: positive predictive value, NPV: negative predictive value.
[31, 41, 42]. It is unclear which group of patients who
have CD should undergo surveillance by CE to detect these
malignancies. The authors suggest that candidates include
elderly patients recently with CD. In addition, individuals
diagnosed in childhood, who are rediagnosed as adults, may
be at increased risk of adenocarcinoma [31].
In conclusion, CE provides diagnostic images of the
small bowel mucosa in patients with CD. At present, CE
oﬀers an alternative to duodenal biopsy in patients unable
or unwilling to undergo conventional upper GI endoscopy.
In addition, CE should be considered in elderly patients with
a new diagnosis of CD or those patients with persistent or
relapsing symptoms.
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